Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.

Abstract

<b>Purpose:</b> Diffuse gliomas are the most common primary tumor of the brain and include different subtypes with diverse prognosis. The genomic characterization of diffuse gliomas facilitates their molecular diagnosis. The anatomical localization of diffuse gliomas complicates access to tumor specimens for diagnosis, in some cases incurring high-risk surgical procedures and stereotactic biopsies. Recently, cell-free circulating tumor DNA (ctDNA) has been identified in the cerebrospinal fluid (CSF) of patients with brain malignancies.<b>Experimental Design:</b> We performed an analysis of <i>IDH1, IDH2, TP53, TERT</i>, ATRX, <i>H3F3A</i>, and <i>HIST1H3B</i> gene mutations in two tumor cohorts from The Cancer Genome Atlas (TCGA) including 648 diffuse gliomas. We also performed targeted exome sequencing and droplet digital PCR (ddPCR) analysis of these seven genes in 20 clinical tumor specimens and CSF from glioma patients and performed a histopathologic characterization of the tumors.<b>Results:</b> Analysis of the mutational status of the <i>IDH1, IDH2, TP53, TERT, ATRX, H3F3A</i>, and <i>HIST1H3B</i> genes allowed the classification of 79% of the 648 diffuse gliomas analyzed, into IDH-wild-type glioblastoma, IDH-mutant glioblastoma/diffuse astrocytoma and oligodendroglioma, each subtype exhibiting diverse median overall survival (1.1, 6.7, and 11.2 years, respectively). We developed a sequencing platform to simultaneously and rapidly genotype these seven genes in CSF ctDNA allowing the subclassification of diffuse gliomas.<b>Conclusions:</b> The genomic analysis of <i>IDH1, IDH2, TP53, ATRX, TERT, H3F3A</i>, and <i>HIST1H3B</i> gene mutations in CSF ctDNA facilitates the diagnosis of diffuse gliomas in a timely manner to support the surgical and clinical management of these patients. <i>Clin Cancer Res; 24(12); 2812-9. ©2018 AACR</i>.